Oncology Database

Selected news for the healthcare topic - Oncology Database, collected since 4/2019. There are 31 items in the archive. This healthcare topic shares news with Infectious Disease and Diagnostic Tests.

Please provide a valid email address.
Shares Healthcare News With (link):
Healthcare Topics

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... tel : 00302841026182,00306932607174 Πληροφορίες Προβολή πλήρους προφίλ Τρίτη, 19 Ιανουαρίου 2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database Cancer shared this article with you from Inoreader Message: Background: The literature on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
9/17/2020 malvern-online.com ... the Emmes SARS-CoV-2 Testing Database. This database serves as the latest addition to the market intelligence products already under DeciBio Consulting’s umbrella. Such products include the Emmes Infectious Disease Database, the Emmes Oncology Database , BioMAP (immuno-oncology biomarkers), Marketbooks, Dexter, and BioTrack, among others. The DeciBio Emmes SARS-CoV-2 Testing Database provides data visualization tools and raw data covering coronavirus testing practices in approximately 400 labs in ...
9/20/2019 DeciBio Consulting Acquires Emmes Group's Molecular Diagnostic (MDx) Testing & Oncology Databases Benzinga DeciBio Consulting, LLC, a precision medicine-focused strategy consulting and market intelligence firm, is pleased to announce it has acquired ownership of the Emmes Molecular Diagnostics (MDx) Infectious Disease Database and the Oncology Database from The Emmes Group Inc., effective January 1, 2020. These acquisitions are positioned to strengthen and expand the solutions DeciBio offers its clients. The Emmes MDx (ID) Database has established itself as a unique and essential ...
9/20/2019 DeciBio Consulting Acquires Emmes Group’s Molecular Diagnostic (MDx) Testing & Oncology Databases truckingnews.us ... WIRE)– infectiousdisease –DeciBio Consulting, LLC, a precision medicine-focused strategy consulting and market intelligence firm, is pleased to announce it has acquired ownership of the Emmes Molecular Diagnostics (MDx) Infectious Disease Database and the Oncology Database from The Emmes Group Inc., effective January 1, 2020. These acquisitions are positioned to strengthen and expand the solutions DeciBio offers its clients. The Emmes MDx (ID) Database has established itself as a unique ...
9/20/2019 DeciBio Consulting Acquires Emmes Group’s Molecular Diagnostic (MDx) Testing & Oncology Databases sys-con.com Blog This DeciBio Consulting, LLC, a precision medicine-focused strategy consulting and market intelligence firm, is pleased to announce it has acquired ownership of the Emmes Molecular Diagnostics (MDx) Infectious Disease Database and the Oncology Database from The Emmes Group Inc., effective January 1, 2020. These acquisitions are positioned to strengthen and expand the solutions DeciBio offers its clients. The Emmes MDx (ID) Database has established itself as a unique ...
9/20/2019 DeciBio Consulting Acquires Emmes Group’s Molecular Diagnostic (MDx) Testing & Oncology Databases BioSpace ... BUSINESS WIRE )-- DeciBio Consulting, LLC, a precision medicine-focused strategy consulting and market intelligence firm, is pleased to announce it has acquired ownership of the Emmes Molecular Diagnostics (MDx) Infectious Disease Database and the Oncology Database from The Emmes Group Inc., effective January 1, 2020. These acquisitions are positioned to strengthen and expand the solutions DeciBio offers its clients. The Emmes MDx (ID) Database has established itself as a unique ...
9/19/2019 DeciBio Consulting Acquires Emmes Group’s Molecular Diagnostic (MDx) Testing & Oncology Databases | Business & Finance | manchestertimes.com Business Wire LOS ANGELES--(BUSINESS WIRE)--Sep 19, 2019-- DeciBio Consulting, LLC, a precision medicine-focused strategy consulting and market intelligence firm, is pleased to announce it has acquired ownership of the Emmes Molecular Diagnostics (MDx) Infectious Disease Database and the Oncology Database from The Emmes Group Inc., effective January 1, 2020. These acquisitions are positioned to strengthen and expand the solutions DeciBio offers its clients. The Emmes MDx (ID) Database has ...
9/19/2019 DeciBio Consulting Acquires Emmes Group’s Molecular Diagnostic (MDx) Testing & Oncology Databases malvern-online.com DeciBio Consulting, LLC, a precision medicine-focused strategy consulting and market intelligence firm, is pleased to announce it has acquired ownership of the Emmes Molecular Diagnostics (MDx) Infectious Disease Database and the Oncology Database from The Emmes Group Inc., effective January 1, 2020. These acquisitions are positioned to strengthen and expand the solutions DeciBio offers its clients. The Emmes MDx (ID) Database has established itself as a unique and essential ...
9/19/2019 DeciBio Consulting Acquires Emmes Group’s Molecular Diagnostic (MDx) Testing & Oncology Databases wapakdailynews.com DeciBio Consulting, LLC, a precision medicine-focused strategy consulting and market intelligence firm, is pleased to announce it has acquired ownership of the Emmes Molecular Diagnostics (MDx) Infectious Disease Database and the Oncology Database from The Emmes Group Inc., effective January 1, 2020. These acquisitions are positioned to strengthen and expand the solutions DeciBio offers its clients. The Emmes MDx (ID) Database has established itself as a unique and essential ...
4/10/2019 Natera Announces Plans to Commercialize Tumor Whole Exome Sequencing from Plasma PR Newswire ... including the ability to design Signatera™ assays when tissue is not available. The assay may also allow researchers to characterize resistance mutations, actionable mutations, neoantigens, and tumor evolution. Finally, this capability will enhance Natera's oncology database by generating valuable new data about tumor evolution over time. The plasma exome service can be ordered as a stand-alone assay, or reflexively for Signatera ctDNA-positive cases. Many researchers want a comprehensive ...